Progyny (PGNY) has come into focus after being removed from the Russell 2000 Dynamic Index, an event that can prompt mechanical buying or selling as index trackers rebalance their portfolios.

Progyny's share price has been firming, with a 16.86% 1 month share price return and an 80.10% 3 month share price return. However, the 1 year total shareholder return of 40.82% contrasts with weaker 3 and 5 year total shareholder returns.

If Progyny's recent index related moves have your attention, this is a good moment to scan other opportunities in healthcare technology through the 40 healthcare AI stocks.

With Progyny now off the Russell 2000 Dynamic Index and the share price already posting strong recent returns, the key question is whether the current valuation still leaves upside on the table or whether the market is already pricing in future growth.

Most Popular Narrative: 2% Overvalued

Progyny's most followed narrative sets a fair value of $29.73, slightly below the last close at $30.22. This puts the current share price just above that framework and turns the spotlight onto the assumptions behind it.

Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.

Curious what kind of revenue trajectory, margin lift, and future earnings multiple are baked into that fair value for Progyny? The narrative leans on a specific growth runway, a step up in profitability, and a leaner share count to justify its view. The exact mix of those moving parts is where the story really gets interesting.

Result: Fair Value of $29.73 (OVERVALUED)

However, Progyny's story could look different if employer cost cutting slows benefit adoption or if regulatory changes curb access to reproductive and women's health services.

Another View on Progyny's Valuation

While the popular Progyny narrative points to a fair value of $29.73 and calls the stock slightly overvalued, the Simply Wall St DCF work presents a different picture. On that model, Progyny at $30.22 trades at a discount to an estimated future cash flow value of $64.47, which indicates a gap in how cash generation is being priced. For an investor weighing these signals, the key question is which set of assumptions appears more realistic.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Progyny for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With the mixed signals around Progyny's valuation and outlook, do you want to rely on others' views or test the numbers yourself? Take a closer look at what investors see as the key potential upsides in our 3 key rewards

Looking for more investment ideas beyond Progyny?

If Progyny has sharpened your focus, do not stop here. Broaden your watchlist with stocks that match your goals using the Simply Wall St screener tools.

• Target potential underpriced opportunities by scanning companies that stand out on valuation and quality through the 44 high quality undervalued stocks.
• Prioritise stability and resilience by checking companies highlighted in the 74 resilient stocks with low risk scores.
• Hunt for fresh prospects off the beaten path with the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.